Late Donor-Specific Antibody (Especially Class II) Development is Associated with an Increased Risk for Cardiac Allograft Vasculopathy.

被引：0
|
作者：
Kransdorf, E. [1 ]
Patel, J. [1 ]
Kittleson, M. [1 ]
Levine, R. [1 ]
Dimbil, S. [1 ]
Geft, D. [1 ]
Chang, D. [1 ]
Czer, L. [1 ]
Kobashigawa, J. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2018年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B73
引用
收藏
页码：653 / 653
页数：1
相关论文
共 50 条
  • [41] Complement Fixing Donor-Specific Antibodies Are Associated with Increased Risk of Chronic Lung Allograft Dysfunction after Lung Transplantation.
    Ensor, C.
    Iasella, C.
    Mangiola, M.
    Marrari, M.
    Morrell, M.
    Shigemura, N.
    DCunha, J.
    McDyer, J.
    Zeevi, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 854 - 855
  • [42] Donor-Transmitted Atherosclerosis and the Occurrence of Cardiac Antibody-Mediated Rejection Influenced on the Development of Cardiac Allograft Vasculopathy
    Watanabe, T.
    Yanase, M.
    Fujita, T.
    Fukushima, S.
    Nakajima, S.
    Kuroda, K.
    Iwasaki, K.
    Yajima, S.
    Tadokoro, N.
    Mochizuki, H.
    Anegawa, E.
    Sujino, Y.
    Yagi, N.
    Yoshitake, K.
    Kobayashi, J.
    Fukushima, N.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S249 - S249
  • [43] ASYMPTOMATIC POSITIVE CMV SEROLOGY IS ASSOCIATED WITH INCREASED RISK FOR THE DEVELOPMENT OF CARDIAC ALLOGRAFT VASCULOPATHY (CAV) AFTER HEART TRANSPLANTATION
    Davis, S.
    Hamilton, M.
    Kobashigawa, J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2010, 58 (01) : 113 - 113
  • [44] HLA Class II Donor-Specific Antibody Desensitization with Nonleukoreduced Irradiated Whole Blood Pretransplant
    Jacob, Reuben
    Tho Pham
    Vina, Marcelo Fernandez
    Zhang, Melody
    Johnston, Laura
    Hussain, Mohammad
    Pandey, Suchitra
    TRANSFUSION, 2019, 59 : 94A - 94A
  • [45] Only Persistent Donor Specific Antibodies are Associated with Subsequent Cardiac Allograft Vasculopathy After Heart Transplantation
    Kobashigawa, J. A.
    Kittleson, M.
    Aintablian, T.
    Azarbal, B.
    Hage, A.
    Kransdorf, E.
    Geft, D.
    Chang, D.
    Czer, L.
    Esmailian, F.
    Zhang, X.
    Reinsmoen, N.
    Patel, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S292 - S292
  • [46] Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study
    Schinstock, Carrie A.
    Dadhania, Darshana M.
    Everly, Matthew J.
    Smith, Byron
    Gandhi, Manish
    Farkash, Evan
    Sharma, Vijay K.
    Samaniego-Picota, Milagros
    Stegall, Mark D.
    TRANSPLANT INTERNATIONAL, 2019, 32 (05) : 502 - 515
  • [47] Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation
    McCaughan, J. A.
    Battle, R. K.
    Singh, S. K. S.
    Tikkanen, J. M.
    Moayedi, Y.
    Ross, H. J.
    Singer, L. G.
    Keshavjee, S.
    Tinckam, K. J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (12) : 2924 - 2933
  • [48] Impact of donor-specific anti-HLA antibody and antibody-mediated rejection on the development of chronic allograft nephropathy
    Simpkins, CE
    Montgomery, RA
    Kaul, S
    Zachary, AA
    Warren, DS
    Sonnenday, C
    Racusen, LC
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 315 - 315
  • [49] HLA FACTORS ASSOCIATED WITH DONOR-SPECIFIC HLA ANTIBODY DEVELOPMENT IN HEART TRANSPLANTED PATIENTS
    Kamenaric, Marija Burek
    Skoric, Bosko
    Palfi, Biserka
    Grubic, Zorana
    Zunec, Renata
    HLA, 2020, 95 (04) : 315 - 315
  • [50] Late Onset Antibody-Mediated Rejection and Endothelial Localization of Vascular Endothelial Growth Factor Are Associated With Development of Cardiac Allograft Vasculopathy
    Bayliss, Julianne
    Bailey, Michael
    Leet, Angeline
    Stein, Alicia N.
    Thomson, Napier M.
    McLean, Catriona A.
    TRANSPLANTATION, 2008, 86 (07) : 991 - 997
12345